The reverse split is a technical fix to maintain listing, not a catalyst for recovery. Given the company's pre-revenue status, repeated dilution, and negative historical stock performance, further capital raises or adverse clinical/regulatory news could drive additional downside. Monitor for compliance status and any financing announcements post-split.
Price Chart
Executive Summary
IceCure Medical announced a 1-for-30 reverse share split effective June 4, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split reduces outstanding shares from ~84.2M to ~2.8M but does not change fundamental value, serving as a technical measure to avoid delisting. Combined with recent equity raises and a history of poor stock performance, the action signals ongoing financial distress.
Key Facts
- 1-for-30 reverse share split approved by board, effective June 4, 2026.
- Outstanding shares reduce from 84,201,034 to approximately 2,806,701.
- Purpose is to meet Nasdaq $1.00 minimum bid price; cure deadline is November 9, 2026.
- Company has a small market cap of ~$16M and pre-revenue status.
- Prior 424B5 equity offer for $4.34M filed 21 days ago, signaling ongoing cash needs.
Financial Impact
No direct financial impact; reverse split does not affect cash or operations.
Risk Factors
- Potential failure to maintain Nasdaq compliance if stock price falls again after split.
- Ongoing cash burn may require additional dilutive financing.
- Reverse splits often signal distress and can lead to further selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063815 |
| Document: ea029311601ex99-1.htm | 0001213900-26-063815 |
| Document: 0001213900-26-063815-index-headers.html | 0001213900-26-063815 |
| Document: 0001213900-26-063815-index.html | 0001213900-26-063815 |
| Document: 0001213900-26-063815.txt | 0001213900-26-063815 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.10 | awaiting T+60 | — | $1.06 (−3.72%) |
Oct 5, 2026 21d ago | 6-K | $1.27 | awaiting T+60 | — | $1.06 (−16.61%) |
Oct 5, 2026 22d ago | 6-K | $1.54 | awaiting T+60 | — | $1.06 (+31.23%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.06 (−50.51%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.06 (−53.34%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.06 (+57.97%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.06 (−62.44%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.06 (−65.89%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.06 (+77.03%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.06 (+79.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers